LSD辅助治疗焦虑患者:开放标签前瞻性12个月随访
该研究为一项双盲、安慰剂对照、两周期交叉试验的预先计划长期随访,39例伴或不伴威胁生命疾病的焦虑患者在接受口服LSD(200 μg)或安慰剂后随访1年。结果显示,与基线相比,STAI-G评分持续降低,合并抑郁症状改善,神经质降低、外向性增加。作者结论为患者报告LSD辅助治疗对焦虑有持续长期效应。
要点
- 第一周期接受LSD者末次治疗后94周STAI-G较基线降低21.6分(95%CI -32.7~-10.4,d=1.04,P<0.001)。
- 第二周期接受LSD者末次治疗后68周STAI-G较基线降低16.5分(95%CI -26.2~-6.8,d=1.02,P<0.05)。
- LSD先治疗组与安慰剂先治疗组BDI较基线分别降低8.1分和8.9分,神经质降低(P<0.0001)、外向性增加(P<0.01)。
核心结论
- 患者报告LSD辅助治疗对焦虑具有持续的长期效应。
研究设计与样本
- 本研究为研究者发起的双中心试验的预先计划长期随访,该试验采用双盲、安慰剂对照、两周期、随机顺序交叉设计,每周期接受口服LSD(200 μg)或安慰剂各一次。
- 共39例伴或不伴威胁生命疾病的焦虑患者纳入分析,在结束研究访视后1年随访焦虑、抑郁症状及致幻剂的长期效应。
- 评估工具包括斯皮尔伯格状态-特质焦虑量表-全局版(STAI-G)、贝克抑郁量表(BDI)、持续效应问卷及NEO五因素人格量表。
主要发现
- 第一周期接受LSD者(末次LSD治疗后94周)STAI-G评分较基线持续降低,最小二乘均值(95%CI)为-21.6(-32.7,-10.4),d=1.04,P<0.001。
- 第二周期接受LSD者(末次LSD治疗后68周)STAI-G评分较基线持续降低,最小二乘均值(95%CI)为-16.5(-26.2,-6.8),d=1.02,P<0.05。
- LSD先治疗组BDI评分较基线变化为-8.1(95%CI -13.2,-3.1),d=0.71,P<0.01;安慰剂先治疗组为-8.9(95%CI -12.9,-4.9),d=1.21,P<0.01。
- 与研究纳入时相比,人格特质神经质降低(P<0.0001),特质外向性增加(P<0.01)。
- 个体将积极的长期效应归因于致幻剂体验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anxiety disorders are a major public health burden with limited treatment options. AIMS: We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness. METHOD: This study was an a priori-planned long-term follow-up of an investigator-initiated, two-centre trial that used a double-blind, placebo-controlled, two-period, random-order, crossover design with two sessions with either oral LSD (200 μg) or placebo per period. Participants (n = 39) were followed up 1 year after the end-of-study visit to assess symptoms of anxiety, depression and long-term effects of psychedelics using Spielberger's State-Trait Anxiety Inventory-Global (STAI-G), the Beck Depression Inventory (BDI), the Persisting Effects Questionnaire and measures of personality traits using the NEO-Five-Factor Inventory. RESULTS: Participants reported a sustained reduction of STAI-G scores compared with baseline (least square means (95% CI) = -21.6 (-32.7, -10.4), d = 1.04, P < 0.001, for those who received LSD in the first period (94 weeks after the last LSD treatment) and -16.5 (-26.2, -6.8), d = 1.02, P < 0.05, for those who received LSD in the second period (68 weeks after the last LSD treatment)). Similar effects were observed for comorbid depression with change from baseline BDI scores of -8.1 (-13.2, -3.1), d = 0.71, P < 0.01, and -8.9 (-12.9, -4.9), d = 1.21, P < 0.01, for the LSD-first and placebo-first groups, respectively. Personality trait neuroticism decreased (P < 0.0001) and trait extraversion increased (P < 0.01) compared with study inclusion. Individuals attributed positive long-term effects to the psychedelic experience. CONCLUSIONS: Patients reported sustained long-term effects of LSD-assisted therapy for anxiety.
引用
- Holze F, Gasser P, Müller F, et al. LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. Br J Psychiatry. 2024. PMID: 39078038. doi:10.1192/bjp.2024.99
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。